Trade

with

Orexigen Therapeutics Inc
(NASDAQ: OREX)
AdChoices
4.39
+0.01
+0.23%
After Hours :
4.39
0.00
0.00%

Open

4.39

Previous Close

4.38

Volume (Avg)

2.04M (4.12M)

Day's Range

4.30-4.42

52Wk Range

3.11-7.82

Market Cap.

536.70M

Dividend Rate ( Yield )

-

Beta

2.51

Shares Outstanding

122.53M

P/E Ratio (EPS)

-

AdChoices
Financials
  • Income Statement
  • Balance Sheet
  • Cash Flow
Operating Income
-77.20M
Operating Margin
-2,251.98
Total Equity
-
Retained Earnings
-
Free Cashflow
-
Price/Cashflow
-
Ownership

Institutional Ownership

75.14%

Top 10 Institutions

40.65%

Mutual Fund Ownership

43.80%

Float

82.16%

5% / Insider Ownership

0.29%

Corporate insiders or major stockholders reporting trading activity in the stock.

Top Mutual Fund Owners

Top Institutional Owners

Mutual Fund Name

Institution Name

  • Mutual Fund Name

  • Shares Held

  • % Change

  • % Outstanding

  • Fidelity® Select Biotechnology Portfolio

  •  

    8,571,509

  • 0.00

  • 7.00

  • VA CollegeAmerica Small Cap World

  •  

    4,719,655

  • -13.56

  • 3.85

  • T. Rowe Price Health Sciences Fund

  •  

    3,718,000

  • 83.32

  • 3.03

  • SPDR® S&P Biotech ETF

  •  

    3,028,899

  • -1.93

  • 2.54

  • Franklin Biotechnology Discovery

  •  

    2,506,277

  • 21.40

  • 2.25

  • Vanguard Total Stock Mkt Idx

  •  

    2,133,366

  • 31.14

  • 1.74

  • American Funds IS® Gbl Sm Cap

  •  

    1,964,900

  • -3.68

  • 1.60

  • iShares Russell 2000 (AU)

  •  

    1,821,265

  • -1.46

  • 1.53

  • DWS Vermögensbildungsfonds

  •  

    1,650,328

  • 22.22

  • 1.35

  • iShares Nasdaq Biotechnology

  •  

    1,585,324

  • -0.47

  • 1.33

  • Institution Name

  • Shares Held

  • % Change

  • % Outstanding

  • Fidelity Management and Research Company

  •  

    9,921,581

  • +43.54%

  • 8.10

  • Capital Research Global Investors

  •  

    9,659,299

  • -7.87%

  • 7.88

  • T. Rowe Price Associates, Inc.

  •  

    4,786,400

  • +81.68%

  • 3.91

  • Partner Fund Management LP

  •  

    4,604,958

  • -10.22%

  • 3.76

  • BlackRock Fund Advisors

  •  

    4,240,589

  • -1.90%

  • 3.46

  • State Street Corp

  •  

    4,139,892

  • -2.34%

  • 3.38

  • Franklin Advisers, Inc.

  •  

    3,651,477

  • -9.35%

  • 2.98

  • Merrill Lynch & Co Inc

  •  

    3,118,748

  • -6.44%

  • 2.55

  • Vanguard Group, Inc.

  •  

    2,992,272

  • +1.19%

  • 2.44

  • Farallon Capital Management, L.L.C.

  •  

    2,684,300

  • 0.00%

  • 2.19

Company Profile

Sector

Healthcare

Industry

Drug Manufacturers – Specific & Generic

Type

Distressed

Style

Small Growth

Orexigen Therapeutics Inc was incorporated in Delaware in September 2002. Company is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates are...more NB32, which has completed Phase III clinical trials and which is currently being studied in a cardiovascular outcomes trial, and Empatic, which has completed Phase II clinical trials. Both NB32 and Empatic regulate appetite and energy expenditure through central nervous system activity. NB32 is a fixed dose combination of bupropion and naltrexone. Company develops its product candidates for large markets traditionally served by primary care physicians. In order to effectively promote NB32 to these physicians, in September 2010, it entered into a collaboration agreement ...morewith Takeda to develop and commercialize NB32 in the United States, Canada and Mexico. It maintains an aggressive intellectual property strategy, which includes patent and trademark filings in multiple jurisdictions including the United States and other commercially significant markets. It relies on a combination of in-licensed patent rights, its own patent rights, trademarks, trade secrets and know-how to protect NB32 and Empatic. Its products used in clinical trials have been produced by outside contractors under its supervision. Company competes with AstraZeneca, Athersys, Inc., Bristol-Myers Squibb, Norgine BV, Novo Nordisk A/S, among others.lessless

Key People

Michael A. Narachi

CEO/President/Director

Dr. Eckard Weber,M.D.

Chairman of the Board/Director/Founder

Joseph P. Hagan

CFO/Chief Accounting Officer/Other Executive Officer/Treasurer

Patrick J. Mahaffy

Director

Brian H. Dovey

Director

Incorporated

2002

Employees

-

Send Feedback

We appreciate your input!

  • I'm having trouble signing into my Microsoft account

  • I’m having problems with the services stripe (Mail, Facebook, etc.)

  • There is an issue with my weather information

  • I see an error in the content

  • Other

Please give an overall site rating: